文献速递类风湿关节炎血管炎

B细胞数量可预测接受利妥昔单抗治疗患者对SARS-CoV-2疫苗接种的体液和细胞免疫应答

B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
PubMed 文献 · Arthritis Rheumatol · 2022-04-17

研究纳入19例接受利妥昔单抗(RTX)治疗的类风湿关节炎(RA)或ANCA相关血管炎患者、12例接受其他治疗的RA患者和30例健康对照,评估SARS-CoV-2疫苗接种后的抗体及抗原特异性B细胞和CD4/CD8 T细胞应答。结果提示外周血B细胞至少10个/微升(淋巴细胞的0.4%)可能是RTX治疗患者实现抗S1 IgG血清阳转的候选生物标志物。

要点

  • 外周血B细胞至少10个/微升(淋巴细胞的0.4%)可能是RTX治疗患者疫苗接种后血清阳转的候选生物标志物。
  • 未出现IgG血清阳转的RTX治疗患者RBD阳性B细胞、Tfh样细胞及活化CD4和CD8 T细胞均减少。
  • 功能性B细胞耗竭导致刺突特异性CD4 T细胞干扰素-γ分泌受损。

核心结论

  • 在接受RTX治疗的患者中,外周血B细胞至少10个/微升是SARS-CoV-2疫苗接种后高概率获得适当细胞和体液应答的候选生物标志物。
  • 数据强调共刺激B细胞功能对正确诱导CD4应答、进而促进疫苗特异性B细胞和浆细胞分化具有关键作用。

研究设计与样本

  • 研究纳入19例接受RTX治疗的RA或ANCA相关血管炎患者、12例接受其他治疗的RA患者和30例健康对照。
  • 受试者在接种SARS-CoV-2疫苗(mRNA疫苗或载体疫苗)后,检测抗体应答及抗原特异性B细胞和CD4/CD8 T细胞亚群。

主要发现

  • 外周血B细胞至少10个/微升(淋巴细胞的0.4%)似乎是RTX治疗患者接种SARS-CoV-2疫苗后产生抗S1 IgG血清阳转所必需的。
  • 与实现IgG血清阳转的RTX治疗患者相比,未实现IgG血清阳转的RTX治疗患者RBD阳性B细胞减少(P=0.0005)、Tfh样细胞频率降低(P=0.0481)、活化CD4 T细胞减少(P=0.0036)、活化CD8 T细胞减少(P=0.0308)。
  • 功能性B细胞耗竭导致刺突特异性CD4 T细胞干扰素-γ分泌受损(P=0.0112,r=0.5342)。
  • 抗原特异性CD8 T细胞在RA患者和RTX治疗患者中均减少,且与IgG形成无关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) therapy are at higher risk of poor COVID-19 outcomes and show substantially impaired humoral immune response to anti-SARS-CoV-2 vaccine. However, the complex relationship between antigen-specific B cells and T cells and the level of B cell repopulation necessary to achieve anti-vaccine responses remain largely unknown. METHODS: Antibody responses to SARS-CoV-2 vaccines and induction of antigen-specific B and CD4/CD8 T cell subsets were studied in 19 patients with rheumatoid arthritis (RA) or antineutrophil cytoplasmic antibody-associated vasculitis receiving RTX, 12 patients with RA receiving other therapies, and 30 healthy controls after SARS-CoV-2 vaccination with either messenger RNA or vector-based vaccines. RESULTS: A minimum of 10 B cells per microliter (0.4% of lymphocytes) in the peripheral circulation appeared to be required for RTX-treated patients to mount seroconversion to anti-S1 IgG upon SARS-CoV-2 vaccination. RTX-treated patients who lacked IgG seroconversion showed reduced receptor-binding domain-positive B cells (P = 0.0005), a lower frequency of Tfh-like cells (P = 0.0481), as well as fewer activated CD4 (P = 0.0036) and CD8 T cells (P = 0.0308) compared to RTX-treated patients who achieved IgG seroconversion. Functionally relevant B cell depletion resulted in impaired interferon-γ secretion by spike-specific CD4 T cells (P = 0.0112, r = 0.5342). In contrast, antigen-specific CD8 T cells were reduced in both RA patients and RTX-treated patients, independently of IgG formation. CONCLUSION: In RTX-treated patients, a minimum of 10 B cells per microliter in the peripheral circulation is a candidate biomarker for a high likelihood of an appropriate cellular and humoral response after SARS-CoV-2 vaccination. Mechanistically, the data emphasize the crucial role of costimulatory B cell functions for the proper induction of CD4 responses propagating vaccine-specific B cell and plasma cell differentiation.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, et al. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. Arthritis Rheumatol. 2022. PMID: 34962360. doi:10.1002/art.42060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。